Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

1.

Erythropoietin: the swinging pendulum.

Oster HS, Neumann D, Hoffman M, Mittelman M.

Leuk Res. 2012 Aug;36(8):939-44. doi: 10.1016/j.leukres.2012.04.017. Epub 2012 May 11. Review.

PMID:
22579365
[PubMed - indexed for MEDLINE]
2.

Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.

Arbuckle RB, Griffith NL, Iacovelli LM, Johnson PE, Jorgenson JA, Kloth DD, Lucarelli CD, Muller RJ.

Pharmacotherapy. 2008 May;28(5 Pt 2):1S-15S. doi: 10.1592/phco.28.5supp.1S.

PMID:
18447704
[PubMed - indexed for MEDLINE]
3.

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.

Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M.

JAMA. 2008 Feb 27;299(8):914-24. doi: 10.1001/jama.299.8.914. Review.

PMID:
18314434
[PubMed - indexed for MEDLINE]
4.

New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.

Steensma DP.

J Support Oncol. 2007 Nov-Dec;5(10):471-3. No abstract available.

PMID:
18240668
[PubMed - indexed for MEDLINE]
5.

Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.

Nowrousian MR, Dunst J, Vaupel P.

Strahlenther Onkol. 2008 Mar;184(3):121-36. doi: 10.1007/s00066-008-1841-3. Review.

PMID:
18330508
[PubMed - indexed for MEDLINE]
6.

CERA: third-generation erythropoiesis-stimulating agent.

Topf JM.

Expert Opin Pharmacother. 2008 Apr;9(5):839-49. doi: 10.1517/14656566.9.5.839. Review.

PMID:
18345959
[PubMed - indexed for MEDLINE]
7.

Impact of erythropoiesis-stimulating agents on red blood cell transfusion in Korea.

Kang RY, Lee J, Lee YH, Lee HS, Jeong JH, Lee YJ.

Int J Clin Pharm. 2012 Aug;34(4):651-7. doi: 10.1007/s11096-012-9660-0. Epub 2012 Jun 23.

PMID:
22729393
[PubMed - indexed for MEDLINE]
8.

The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.

Hedley BD, Allan AL, Xenocostas A.

Clin Cancer Res. 2011 Oct 15;17(20):6373-80. doi: 10.1158/1078-0432.CCR-10-2577. Epub 2011 Jul 12. Review.

PMID:
21750199
[PubMed - indexed for MEDLINE]
Free Article
9.

Erythropoietin in cancer patients.

Glaspy JA.

Annu Rev Med. 2009;60:181-92. doi: 10.1146/annurev.med.60.050307.110718. Review.

PMID:
18980468
[PubMed - indexed for MEDLINE]
10.

2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.

Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.

Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.

PMID:
20609178
[PubMed - indexed for MEDLINE]
11.

Erythropoietin in cancer-related anemia.

Fenner MH, Ganser A.

Curr Opin Oncol. 2008 Nov;20(6):685-9. doi: 10.1097/CCO.0b013e3283136971. Review.

PMID:
18841051
[PubMed - indexed for MEDLINE]
12.

Rebates for anti-anemia drugs draw response from FDA, CMS.

Sipkoff M.

Manag Care. 2007 Jun;16(6):17-8. No abstract available.

PMID:
17682732
[PubMed - indexed for MEDLINE]
Free Article
13.

Erythropoiesis-stimulating agents for anemic patients with cancer.

Sheikh S, Littlewood TJ.

Expert Rev Hematol. 2010 Dec;3(6):697-704. doi: 10.1586/ehm.10.64. Review.

PMID:
21091146
[PubMed - indexed for MEDLINE]
14.

The FDA black box for EPO: what should nephrologists do?

Singh AK.

Nephrol News Issues. 2007 May;21(6):55-6, 58-9. No abstract available.

PMID:
17518125
[PubMed - indexed for MEDLINE]
15.

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.

Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B.

Br J Cancer. 2012 Mar 27;106(7):1249-58. doi: 10.1038/bjc.2012.42. Epub 2012 Mar 6. Review.

PMID:
22395661
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Reevaluating erythropoiesis-stimulating agents.

Cotter DJ.

N Engl J Med. 2010 May 6;362(18):1743; author reply 1743-4. No abstract available.

PMID:
20449881
[PubMed - indexed for MEDLINE]
17.

Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.

Luo W, Nordstrom BL, Fraeman K, Nordyke R, Ranganathan G, Linz HE, Winterkorn A, Stokes M, Ross SD, Knopf K.

Clin Ther. 2008 Dec;30(12):2423-35. doi: 10.1016/j.clinthera.2008.12.022.

PMID:
19167601
[PubMed - indexed for MEDLINE]
18.

Tumor progression associated with erythropoiesis-stimulating agents.

Newland AM, Black CD.

Ann Pharmacother. 2008 Dec;42(12):1865-70. doi: 10.1345/aph.1L231. Epub 2008 Nov 18. Review.

PMID:
19017828
[PubMed - indexed for MEDLINE]
19.

Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia.

Lappin TR, Maxwell AP, Johnston PG.

Oncologist. 2007 Apr;12(4):362-5. No abstract available.

PMID:
17470677
[PubMed - indexed for MEDLINE]
Free Article
20.

Erythropoietin, the FDA, and oncology.

Steinbrook R.

N Engl J Med. 2007 Jun 14;356(24):2448-51. No abstract available.

PMID:
17568025
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk